Achievement of avian influenza virus-like particles that could be used as a subunit vaccine against low-pathogenic avian influenza strains in ducks

Avian Pathology

Volumn 37, Issue 5, 2008, Pages 513-520

  Prel, Anne ^a   Le Gall Reculé, Ghislaine ^a   Jestin, Véronique ^a  

^a Healthy Pigs Production and Experimentation Section   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HEMAGGLUTININ, AVIAN INFLUENZA A VIRUS; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; VIRUS ANTIBODY;

ANIMAL; ARTICLE; AVIAN INFLUENZA; BACULOVIRUS; CELL LINE; DOSE RESPONSE; DUCK; GENE EXPRESSION REGULATION; GENETIC RECOMBINATION; GENETICS; IMMUNOLOGY; INFLUENZA VIRUS A; INSECT; PATHOGENICITY; PLASMID; VIROLOGY;

ANIMALS; ANTIBODIES, VIRAL; BACULOVIRIDAE; CELL LINE; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; DUCKS; GENE EXPRESSION REGULATION, VIRAL; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; INFLUENZA A VIRUS; INFLUENZA IN BIRDS; INFLUENZA VACCINES; INSECTS; PLASMIDS; RECOMBINATION, GENETIC;

ANAS; ANAS PLATYRHYNCHOS; ANIMALIA; AVES; AVIAN INFLUENZA VIRUS; CAIRINA MOSCHATA; ORTHOMYXOVIRIDAE;

EID: 51849107047     PISSN: 03079457     EISSN: 14653338     Source Type: Journal    
DOI: 10.1080/03079450802357001     Document Type: Article

References (27)

1. Brett, I.C. & Johansson, B.E. (2005). Immunization against influenza A virus: comparison of conventional inactivated, live-attenuated and recombinant baculovirus produced purified hemagglutinin and neuraminidase vaccines in a murine model system. Virology, 339, 273-280.
2. Bright, R.A., Carter, D.M., Daniluk, S., Toapanta, F.R., Ahmad, A., Gavrilov, V., Massare, M., Pushko, P., Mytle, N., Rowe, T., Smith, G. & Ross, T.M. (2007). Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin. Vaccine, 25, 3871-3878.
3. Bright, R.A., Carter, D.M., Crevar, C.J., Toapanta, F.R., Steckbeck, J.D., Cole, K.S., Kumar, N.M., Pushko, P., Smith, G., Tumpey, T.M. & Ross, T.M. (2008). Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle. PLoS ONE, 3, e1501.
4. Chen, B.J., Leser, G.P., Morita, E. & Lamb, R.A. (2007). Influenza virus hemagglutinin and neuraminidase, but not the matrix protein, are required for assembly and budding of plasmid-derived virus-like particles. Journal of Virology, 81, 7111-7123.
5. Cherbonnel, M., Lamande, J., Allee, C., Schmitz, A., Ogor, K., Le Gall-Reculé, G., Le Bras, M.O., Guillemoto, C., Pierre, I., Picault, J.P. & Jestin, V. (2007). Virologic findings in selected free-range mule duck farms at high risk for avian influenza infection. Avian Diseases, 51, 408-413.
6. Crawford, J., Wilkinson, B., Vosnesensky, A., Smith, G., Garcia, M., Stone, H. & Perdue, M.L. (1999). Baculovirus-derived hemagglutinin vaccines protect against lethal influenza infections by avian H5 and H7 subtypes. Vaccine, 17, 2265-2274.
7. Galarza, J.M., Latham, T. & Cupo, A. (2005). Virus-like particle (VLP) vaccine conferred complete protection against a lethal influenza virus challenge. Viral Immunology, 18, 244-251.
8. Gomez-Puertas, P., Albo, C., Perez-Pastrana, E., Vivo, A. & Portela, A. (2000). Influenza virus matrix protein is the major driving force in virus budding. Journal of Virology, 74, 11538-11547.
9. Latham, T. & Galarza, J.M. (2001). Formation of wild-type and chimeric influenza virus-like particles following simultaneous expression of only four structural proteins. Journal of Virology, 75, 6154-6165.
10. Lohmeyer, J., Talens, L.T. & Klenk, H.D. (1979). Biosynthesis of the influenza virus envelope in abortive infection. Journal of General Virology, 42, 73-88.
11. Matassov, D., Cupo, A. & Galarza, J.M. (2007). A novel intranasal virus-like particle (VLP) vaccine designed to protect against the pandemic 1918 influenza A virus (H1N1). Viral Immunology, 20, 441-452.
12. Middleton, D., Bingham, J., Selleck, P., Lowther, S., Gleeson, L., Lehrbach, P., Robinson, S., Rodenberg, J., Kumar, M. & Andrew, M. (2007). Efficacy of inactivated vaccines against H5N1 avian influenza infection in ducks. Virology, 359, 66-71.
13. Noad, R. & Roy, P. (2003). Virus-like particles as immunogens. Trends in Microbiology, 11, 438-444.
14. OI (2008). Update on Avian Influenza. Available online at: http://www.oie.int/downld/Avian%200influenza/a_AI-Asia.htm.
15. OIE (2004). Highly Pathogenic Avian Influenza. OIE Manual of Diagnostic Tests and Vaccines for Terrestrial Animals (Mammals, Birds, and Bees) 5th edn. Paris, France: OIE.
16. Prel, A., Le Gall-Reculé, G., Cherbonnel, M., Grasland, B., Amelot, M. & Jestin, V. (2007). Assessment of the protection afforded by triple baculovirus recombinant coexpressing H5, N3, M1 proteins against a homologous H5N3 low-pathogenicity avian influenza virus challenge in Muscovy ducks. Avian Diseases, 51, 484-489.
17. Pushko, P., Tumpey, T.M., Bu, F., Knell, J., Robinson, R. & Smith, G. (2005). Influenza virus-like particles comprised of the HA, NA, and M1 proteins of H9N2 influenza virus induce protective immune responses in BALB/c mice. Vaccine, 23, 5751-5759.
18. Pushko, P., Tumpey, T.M., Van Hoeven, N., Belser, J.A., Robinson, R., Nathan, M., Smith, G., Wright, D.C. & Bright, R.A. (2007). Evaluation of influenza virus-like particles and Novasome adjuvant as candidate vaccine for avian influenza. Vaccine, 25, 4283-4290.
19. Quan, F.S., Huang, C., Compans, R.W. & Kang, S.M. (2007). Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus. Journal of Virology, 81, 3514-3524.
20. Roberts, P.C., Lamb, R.A. & Compans, R.W. (1998). The M1 and M2 proteins of influenza A virus are important determinants in filamentous particle formation. Virology, 240, 127-137.
21. Roy, P. (1996). Genetically engineered particulate virus-like structures and their use as vaccine delivery systems. Intervirology, 39, 62-71.
22. Steensels, M., Van Borm, S., Lambrecht, B., De Vriese, J., Le Gros, F.X., Bublot, M. & van den Berg, T. (2007). Efficacy of an inactivated and a fowlpox-vectored vaccine in Muscovy ducks against an Asian H5N1 highly pathogenic avian influenza viral challenge. Avian Diseases, 51, 325-331.
23. Sturm-Ramirez, K.M., Hulse-Post, D.J., Govorkova, E.A., Humberd, J., Seiler, P., Puthavathana, P., Buranathai, C., Nguyen, T.D., Chaisingh, A., Long, H.T., Naipospos, T.S., Chen, H., Ellis, T.M., Guan, Y., Peiris, J.S. & Webster, R.G. (2005). Are ducks contributing to the endemicity of highly pathogenic H5N1 influenza virus in Asia? Journal of Virology, 79, 11269-11279.
24. Swayne, D.E., Beck, J.R. & Kinney, N. (2000). Failure of a recombinant fowl poxvirus vaccine containing an avian influenza hemagglutinin gene to provide consistent protection against influenza in chickens preimmunized with a fowl pox vaccine. Avian Diseases, 44, 132-137.
25. van den Berg, T., Lambrecht, B., Marche, S., Steensels, M., Van Borm, S. & Bublot, M. (2008). Influenza vaccines and vaccination strategies in birds. Comparative Immunology Microbiology and Infectious Disease, 31, 121-165.
26. van Deusen, R.A., Hinshaw, V.S., Senne, D.A. & Pellacani, D. (1983). Micro neuraminidase-inhibition assay for classification of influenza A virus neuraminidases. Avian Diseases, 27, 745-750.
27. van Oers, M.M. (2006). Vaccines for viral and parasitic diseases produced with baculovirus vectors. Advance in Virus Research, 68, 193-253.